Proton pump inhibitors long term use‐ trends and patterns over 15 years of a large health maintenance organization

2021 ◽  
Author(s):  
Vered Rosenberg ◽  
Roie Tzadok ◽  
Gabriel Chodick ◽  
Kariv Revital
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Health Maintenance Organization ◽  
Health Maintenance

Use of proton-pump inhibitors at a nonprofit, mixed-model health maintenance organization

2004 ◽  
Vol 61 (21) ◽  
pp. 2244-2244
Author(s):  
Michele B. Kaufman ◽  
Kaliroi Alimonos ◽  
Araksi Sarafian
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Mixed Model ◽  
Health Maintenance Organization ◽  
Health Maintenance

Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury

2021 ◽  
Author(s):  
Yutaka Hatakeyama ◽  
Taro Horino ◽  
Tatsuki Matsumoto ◽  
Yoshio Terada ◽  
Yoshiyasu Okuhara
Keyword(s):  
Acute Kidney Injury ◽  
Renal Function ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Kidney Injury ◽  
Renal Function Decline ◽  
Continuous Use

scholarly journals Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Simone Janett ◽  
Pietro Camozzi ◽  
Gabriëlla G. A. M. Peeters ◽  
Sebastiano A. G. Lava ◽  
Giacomo D. Simonetti ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Treatment ◽  
Cross Sectional ◽  
Magnesium Metabolism ◽  
Poor Renal Function ◽  
Long Term Treatment

In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.

scholarly journals Severe hypomagnesaemia in long-term users of proton-pump inhibitors

2008 ◽  
Vol 69 (2) ◽  
pp. 338-341 ◽  
Author(s):  
T. Cundy ◽  
A. Dissanayake
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump

The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin

2014 ◽  
Vol 46 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Hólmfridur Helgadóttir ◽  
David C. Metz ◽  
Yu-Xiao Yang ◽  
Andrew D. Rhim ◽  
Einar S. Björnsson
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Term Therapy ◽  
Long Term Therapy

Perils and pitfalls of long-term effects of proton pump inhibitors

2013 ◽  
Vol 6 (4) ◽  
pp. 443-451 ◽  
Author(s):  
Sheila M Wilhelm ◽  
Ryan G Rjater ◽  
Pramodini B Kale-Pradhan
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Long Term Effects

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial

2006 ◽  
Vol 24 (6) ◽  
pp. 945-954 ◽  
Author(s):  
E. BJORNSSON ◽  
H. ABRAHAMSSON ◽  
M. SIMREN ◽  
N. MATTSSON ◽  
C. JENSEN ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Controlled Trial ◽  
Term Therapy ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Therapy

scholarly journals Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study

Gut ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Ka Shing Cheung ◽  
Esther W Chan ◽  
Angel Y S Wong ◽  
Lijia Chen ◽  
Ian C K Wong ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Proportional Hazards Model ◽  
Absolute Risk ◽  
Eradication Therapy ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model

ObjectiveProton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy.DesignsThis study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012. Patients who failed this regimen, and those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after therapy were excluded. Prescriptions of PPIs or histamine-2 receptor antagonists (H2RA) started within 6 months before GC were excluded to avoid protopathic bias. We evaluated GC risk with PPIs by Cox proportional hazards model with propensity score adjustment. H2RA was used as a negative control exposure.ResultAmong the 63 397 eligible subjects, 153 (0.24%) developed GC during a median follow-up of 7.6 years. PPIs use was associated with an increased GC risk (HR 2.44, 95% CI 1.42 to 4.20), while H2RA was not (HR 0.72, 95% CI 0.48 to 1.07). The risk increased with duration of PPIs use (HR 5.04, 95% CI 1.23 to 20.61; 6.65, 95% CI 1.62 to 27.26 and 8.34, 95% CI 2.02 to 34.41 for ≥1 year, ≥2 years and ≥3 years, respectively). The adjusted absolute risk difference for PPIs versus non-PPIs use was 4.29 excess GC (95% CI 1.25 to 9.54) per 10 000 person-years.ConclusionLong-term use of PPIs was still associated with an increased GC risk in subjects even after HP eradication therapy.

Sign in / Sign up

Export Citation Format

Share Document